relapse-remitting multiple sclerosis (RRMS)

April 2, 2019March 29, 2019

Mayzent Joins the MS Medication Arsenal, But I Have Questions

Columns, The MS Wire - A Column by Ed Tobias

As you might have heard, a disease-modifying therapy (DMT) for patients with active secondary progressive multiple sclerosis (SPMS) was approved a few days ago. That’s great news. A medication ... Read more

May 2, 2018May 16, 2018

#AAN2018 — Lemtrada Sustains Long-Term Benefits for RRMS Patients, TOPAZ Study Shows

Lemtrada, News

Lemtrada (alemtuzumab) can sustain reduced activity and prevent progression of relapsing-remitting multiple sclerosis (RRMS) for more than seven years, clinical data from the CARE-MS extension trial shows. Findings were recently ... Read more

April 25, 2018

#AAN2018 — ALKS 8700 Shows Promise as RRMS Therapy, Phase 3 Trial Interim Results Suggest

News

A one-year analysis of the ongoing Phase 3 EVOLVE-MS-1 trial of ALKS 8700 as a therapy for relapsing remitting multiple sclerosis (RRMS) supports the experimental therapy’s effectiveness, with the treatment ... Read more

October 9, 2017October 19, 2017

BETACONNECT Auto-injector Helps MS Patients Stick with Treatment, Study Reports

News

Most multiple sclerosis patients who try Bayer’s BETACONNECT auto-injector stick with their treatment, a study reports. The electronic product may overcome the problem of many patients failing to stick to a therapy ... Read more

February 12, 2016February 12, 2016

RedHill’s Experimental MS Therapy, RHB-104, Receives Notice of Allowance on U.S. Patent

News

RedHill Biopharma, Ltd., an Israeli biopharmaceutical company focused on the development and commercialization of oral-administered small-molecule medicines for the treatment of inflammatory and gastrointestinal diseases, recently announced it has ... Read more

January 7, 2016January 7, 2016

MS Drug Under Study No Longer Being Given in Higher Doses to Patients

News

Teva Pharmaceutical Industries Ltd. and Active Biotech have discontinued the use of higher doses of the drug laquinimod in two ongoing multiple sclerosis (MS) studies. The decision was based ... Read more

Pin It on Pinterest